Shots:

• The pivotal P-III MONALEESA-7 study assessing Kisqali + endocrine therapy vs PBO + endocrine therapy- in pre- & perimenopausal women with HR+/HER2- advanced or metastatic-BC
• The study met its 2EPs of OS- demonstrating a significant improvement in OS- and is consistent for the NSAI population & across exploratory subgroups- m-OS was not reached while the median duration of follow-up was 34.6 mos.
• Kisqali is a selective cyclin-dependent kinase inhibitor- acts by inhibiting two proteins called CDK4/6

­ Ref: Novartis | Image: Novatis